Ondansetron augmentation for the management of obsessive-compulsive disorder in a patient with treatment-resistant schizophrenia

Aust N Z J Psychiatry. 2021 Aug;55(8):830-831. doi: 10.1177/0004867420963726. Epub 2020 Oct 7.

Authors

Suresh Yadav¹, Anna Takács¹, Christos Pantelis^{1

2}, Naveen Thomas^{1

2}

Affiliations

¹ Adult Mental Health Rehabilitation Unit, NorthWestern Mental Health, Melbourne Health, Sunshine Hospital, St Albans, VIC, Australia.
² Melbourne Neuropsychiatry Centre, Department of Psychiatry, Western Centre for Health & Education, The University of Melbourne and Melbourne Health, St Albans, VIC, Australia.

PMID: 33028077
DOI: 10.1177/0004867420963726

No abstract available

Publication types

Letter

MeSH terms

Humans
Obsessive-Compulsive Disorder* / drug therapy
Ondansetron
Schizophrenia* / drug therapy
Selective Serotonin Reuptake Inhibitors

Substances

Serotonin Uptake Inhibitors
Ondansetron